Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Yкраїнський (UK)
Przejdź do strony domowej biblioteki Centralna Biblioteka Wojskowa Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaCentralna Biblioteka Wojskowa

Wyszukujesz frazę "Debska-Slizien, Alicja" wg kryterium: Autor

  Lista filtrów
Wyrównaj
    Wyświetlanie 1-4 z 4
    Tytuł:
    The use of over-the-counter analgesics in patients with chronic kidney disease
    Autorzy:
    Jakimowicz-Tylicka, Marzena
    Chmielewski, Michał
    Kuźmiuk-Glembin, Izabella
    Skonieczny, Piotr
    Dijakiewicz, Grażyna
    Zdrojewska, Grażyna
    Rutkowski, Bolesław
    Tylicki, Leszek
    Dębska-Ślizień, Alicja
    Powiązania:
    https://bibliotekanauki.pl/articles/895741.pdf
    Data publikacji:
    2019-02-05
    Wydawca:
    Gdański Uniwersytet Medyczny
    Tematy:
    chronic kidney disease
    analgesics
    over-the-counter
    Opis:
    Background: Analgesics can be sold following medical prescription, but also as over-the-counter (OTC) medications. In patients with chronic kidney disease (CKD), their use could potentially be associated with increased risk of side-effects, due to impaired renal elimination. The aim was to evaluate the epidemiology and indications for the use of OTC analgesics, and the knowledge of their side-effects in patients with CKD. Material and methods: A cross-sectional, controlled survey on the use of OTC analgesic drugs was conducted among 180 CKD patients (stage 1-5, dialysis, kidney transplant), compared to 60 controls. Results: The proportion of patients using OTC analgesics on a regular basis was higher in the CKD group, compared to controls (18.9% vs. 10.0%, p<0.02). The major indications included musculoskeletal issues, followed by headaches and other. Subgroup analysis revealed that analgesic use was lowest among transplanted patients, in comparison to CKD stage 1-5, and dialysis subjects (10%, 20%, 26%, respectively, p=0.06). Less than half of CKD patients and controls declared any knowledge on potential side-effects of analgesic drugs (45.6% vs. 40.0%, NS). Conclusions: The use of OTC analgesics among patients with CKD is higher than in subjects without CKD, with the exception of transplanted patients. The knowledge on the potential side-effect of analgesics is limited.
    Źródło:
    European Journal of Translational and Clinical Medicine; 2018, 1, 2; 11-16
    2657-3148
    2657-3156
    Pojawia się w:
    European Journal of Translational and Clinical Medicine
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Dietary supplement use among patients with chronic kidney disease
    Autorzy:
    Jakimowicz-Tylicka, Marzena
    Chmielewski, Michał
    Kuźmiuk-Glembin, Izabella
    Skonieczny, Piotr
    Dijakiewicz, Grażyna
    Zdrojewska, Grażyna
    Rutkowski, Bolesław
    Tylicki, Leszek
    Dębska Ślizień, Alicja
    Powiązania:
    https://bibliotekanauki.pl/articles/1038410.pdf
    Data publikacji:
    2018
    Wydawca:
    Polskie Towarzystwo Biochemiczne
    Tematy:
    dietary supplements
    vitamins
    minerals
    chronic kidney disease
    dialysis
    toxicity
    Opis:
    Background. Dietary supplements (DS) are available over the counter, but patients with impaired renal function are specifically at risk for toxicity when consuming certain DS. The aim of this study was to evaluate the prevalence and characteristics of DS use in patients with chronic kidney disease (CKD). Material and methods. A cross-sectional, controlled DS use survey (22 questions) was conducted among 180 CKD patients (stage 1-5, dialysis, kidney transplant), with 60 patients without CKD serving as controls. Results. DS use did not differ significantly between subjects with and without CKD, unless the CKD patients were on dialysis. In the CKD group, 20% admitted to use DS regularly and 22% did not take the mat all. In the controls, DS consumption was 17% and 13%, respectively (NS). The DS use was higher among women ascompared to men (89% vs. 70%; p < 0.005), and people living in cities versus those living in the country side (81% vs. 63%; p < 0.05). DS most commonly used were: vitamins, minerals, and herbs. Major indications for DS use included: musculoskeletal issues, general health improvement and prevention of urinary tract infections. Subgroup analyses revealed that dialysis patients were characterized by a significantly higher DS use in comparison to CKD stage 1-5 subjects and renal transplant recipients. The decision to introduce DS was made by the physician in 54% of cases; by a pharmacist in 9% of cases, and by the patients themselves in 37%. Only 21% of patients with CKD, and 27% of subjects without CKD, declared knowledge of any possible side-effects associated with DS (NS). Conclusions. The use of DS among patients with CKD is similar to patients without CKD, with the exception of those on dialysis. Vitamins and minerals were the most commonly reported DS consumed. The knowledge on potential side-effectof DS was limited to approximately one-fourth of those surveyed.
    Źródło:
    Acta Biochimica Polonica; 2018, 65, 2; 319-324
    0001-527X
    Pojawia się w:
    Acta Biochimica Polonica
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Aliskiren reduces albuminuria after kidney transplantation
    Autorzy:
    Tylicki, Leszek
    Debska-Slizien, Alicja
    Lizakowski, Slawomir
    Przybylska, Milena
    Heleniak, Zbigniew
    Renke, Marcin
    Chamienia, Andrzej
    Biedunkiewicz, Bogdan
    Rutkowski, Przemyslaw
    Małgorzewicz, Sylwia
    Rutkowski, Boleslaw
    Powiązania:
    https://bibliotekanauki.pl/articles/1038634.pdf
    Data publikacji:
    2017
    Wydawca:
    Polskie Towarzystwo Biochemiczne
    Tematy:
    albuminuria
    aliskiren
    kidney transplantation
    renoprotection
    Opis:
    Background: The renoprotective effects of the direct renin inhibitor, aliskiren, in renal transplant recipients have been supposed, but not finally proven. We performed an exploratory double-blind, losartan controlled, cross-over study to evaluate the influence of aliskiren, direct renin inhibitor, on albuminuria and other surrogate markers of kidney injury in patients after renal transplantation. The safety of this therapy was also evaluated. Method: 16 of 18 patients (12 M, 4 F), 48.3 ± 9.0 years, 57.7 ± 9.1 months after kidney transplantation, with hypertension and stable serum creatinine 1.4 ± 0.08 mg/dl without proteinuria, completed the protocol. Each patient underwent two 8-week treatment periods (one with 150 mg of aliskiren, and one with 50 mg of losartan) in random order, allowing an 8-week placebo washout between them. Results: There were no differences in albuminuria, transforming growth factor β-1 and 15-F2t-isoprostanes urine excretion between aliskiren and losartan. Creatinine serum level, eGFR, 24 h systolic and 24 h diastolic blood pressure were stable through the study. There were no differences in haemoglobin and potassium serum concentration between studied drugs. Conclusion: Aliskiren decreases albuminuria in renal transplant recipients with clinically minimal side effects. The effect does not differ from that of losartan.
    Źródło:
    Acta Biochimica Polonica; 2017, 64, 2; 221-226
    0001-527X
    Pojawia się w:
    Acta Biochimica Polonica
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    SARS-CoV-2 infection in vaccinated maintenance hemodialysis patients despite anti-spike seroconversion: a report of 3 breakthrough cases
    Autorzy:
    Biedunkiewicz, Bogdan
    Tylicki, Leszek
    Puchalska-Reglińska, Ewelina
    Dąbrowska, Małgorzata
    Ślizień, Waldemar
    Kubanek, Alicja
    Rąbalski, Łukasz
    Kosiński, Maciej
    Grzybek, Maciej
    Renke, Marcin
    Dębska-Ślizień, Alicja
    Powiązania:
    https://bibliotekanauki.pl/articles/2203183.pdf
    Data publikacji:
    2022-03-01
    Wydawca:
    Gdański Uniwersytet Medyczny
    Tematy:
    SARS-CoV-2
    breakthrough infection
    hemodialysis
    vaccination
    Opis:
    Chronically hemodialyzed (HD) patients are at a high risk of developing very severe forms of COVID-19 disease. In this article we describe three HD patients (all males, aged 70, 70 and 74 years) vaccinated intramuscularly with a two-dose mRNA BNT162b2 vaccine; BionTech/Pfizer Comirnaty, in whom subsequent breakthrough SARS-CoV-2 infections developed. All patients achieved post-vaccine seroconversion for anti-spike antibodies with IgG titers of 445, 227 and 92.5 AU/mL (cut-off, 13 AU/mL) case 1, 2 and 3 respectively. SARS-CoV-2 infection was diagnosed 44, 28 and 48 days after the second dose of BNT162b2 and confirmed with the polymerase-chain-reaction (PCR) test. Two asymptomatic patients underwent this test because of their direct contact with a person with confirmed COVID-19. The third patient reported only a non-significant drop in oxygen saturation, and was hospitalized (case 3). All these patients were characterized by a low post-vaccination neutralizing antibody titer and a high production of these antibodies after falling ill (795, 845 and 5770). Perhaps this production of antibodies is responsible for the mild course of the disease, and the likely reduction of mortality. These breakthrough cases in no way undermine the importance of the vaccinations, and on the contrary argue for their urgency.
    Źródło:
    European Journal of Translational and Clinical Medicine; 2022, 5, 1; 12-16
    2657-3148
    2657-3156
    Pojawia się w:
    European Journal of Translational and Clinical Medicine
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
      Wyświetlanie 1-4 z 4

      Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies